Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, November 29 2022 - 21:15
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife(R) Satylia(R) in Germany
PARIS, Nov. 29, 2022 /PRNewswire-AsiaNet/ --

TargEDys and SymbioPharm signed an exclusive marketing and distribution 
agreement for the launch of SymbioLife(R) Satylia(R) in Germany. The novel 
dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 
will be available from January 2023.

SymbioLife(R) Satylia(R) is a precision probiotic with a characterized 
mechanism of action at molecular level: it increases satiety thanks to the 
protein ClpB produced by Hafnia alvei HA4597. ClpB naturally mimics the human 
satiety hormone alpha-MSH. The improved feeling of satiety helps with 
successful weight loss, as confirmed by a clinical study with 230 overweight 
adults. This natural principle provided by SymbioLife(R) Satylia(R) is a 
multi-awarded new, natural, safe and effective weight management solution.

Gregory Lambert, CEO of TargEDys: "We are extremely proud and excited about 
this new collaboration. SymbioPharm is in the top 3 of the German probiotics 
market and fathered one of the first probiotic pharmaceuticals globally. With 
the team's knowledge of probiotic Enterobacteria, their strong position with 
doctors, pharmacies, and synergies with probiotics and diagnostics, they are 
the perfect partner for this highly scientific product."

Juergen Eck, Co-CEO and CTO of SymbioPharm:
"We are very excited to partner with TargEDys and work together on a new era of 
evidence-based probiotics. With the patent-protected probiotic Hafnia alvei 
HA4597, its biological mechanism of action and outstanding studies, we can 
offer an effective solution for the growing problems of obesity and metabolic 
health. As pioneers in microbiome research and medical probiotics, we are proud 
to now also help shape the introduction of knowledge-based precision 

About SymbioPharm
SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based 
probiotics - since 1954. Its mission is to preserve health and to heal diseases 
with probiotic bacteria – making use of purely biological effect of natural 
bacteria. Therefore, it researches the human microbiome and develops innovative 
microbiological therapy approaches. The company holds a state-of-the-art 
production facility, and showcases comprehensive expertise from diagnostics – 
with the Institute for Microecology – to innovative solutions.

About TargEDys(R)
TargEDys(R) is a commercial-stage French biotech specialized in the development 
of nutraceutical solutions through microbiome interventions. The company is 
based on 15 years of research on the microbiota conducted within academic 
laboratories. TargEDys(R)' portfolio focuses on overweight, undernutrition, and 
mental health, all based on the concept of PreciBiomic strains backed by a 
molecular mechanism of action and in vivo studies.

Arnaud Faure & Nina Vinot

Logo -